AR047159A1 - Medicamento que comprende inhibidores de pentraxina larga ptx3 - Google Patents
Medicamento que comprende inhibidores de pentraxina larga ptx3Info
- Publication number
- AR047159A1 AR047159A1 ARP040104816A ARP040104816A AR047159A1 AR 047159 A1 AR047159 A1 AR 047159A1 AR P040104816 A ARP040104816 A AR P040104816A AR P040104816 A ARP040104816 A AR P040104816A AR 047159 A1 AR047159 A1 AR 047159A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitors
- medicinal product
- long pentraxin
- ptx3
- ptx3 long
- Prior art date
Links
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 title abstract 2
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 title abstract 2
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4737—C-reactive protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
Abstract
Uso de inhibidores de pentraxina larga PTX3 para la preparacion de un medicamento para la prevencion y el tratamiento de enfermedades autoinmunes y de enfermedades degenerativas de hueso y cartílago.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000596A ITRM20030596A1 (it) | 2003-12-23 | 2003-12-23 | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047159A1 true AR047159A1 (es) | 2006-01-11 |
Family
ID=34708534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104816A AR047159A1 (es) | 2003-12-23 | 2004-12-21 | Medicamento que comprende inhibidores de pentraxina larga ptx3 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20070098722A1 (es) |
EP (1) | EP1706144A2 (es) |
JP (1) | JP2007517021A (es) |
KR (1) | KR20070000415A (es) |
CN (1) | CN1893975A (es) |
AR (1) | AR047159A1 (es) |
AU (1) | AU2004305341A1 (es) |
BR (1) | BRPI0418017A (es) |
CA (1) | CA2548452A1 (es) |
IT (1) | ITRM20030596A1 (es) |
MX (1) | MXPA06007080A (es) |
TW (1) | TW200526246A (es) |
WO (1) | WO2005060997A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
WO2007128647A1 (en) | 2006-05-02 | 2007-11-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION |
WO2009075881A2 (en) * | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
KR101305515B1 (ko) * | 2011-06-10 | 2013-09-06 | 경북대학교 산학협력단 | 펜트락신 3 단백질의 파킨슨 질환 진단 용도 |
EP2934497B1 (en) | 2012-12-21 | 2016-11-23 | Teikoku Pharma USA, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
CN109477088A (zh) * | 2016-05-13 | 2019-03-15 | 国立大学法人东京大学 | 通过肝分泌代谢调节剂抑制作用的肥胖相关疾病的治疗剂 |
CN106950366B (zh) * | 2017-02-15 | 2019-03-22 | 中国医学科学院北京协和医院 | 一种acpa阴性的ra诊断标志物及其应用 |
WO2019056991A1 (zh) * | 2017-09-19 | 2019-03-28 | 臻崴生物科技有限公司 | 单克隆抗体或其抗原结合片段及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
US20030195167A1 (en) * | 2002-04-15 | 2003-10-16 | Kowa Co., Ltd. | PTX3-gene expression inhibitor |
-
2003
- 2003-12-23 IT IT000596A patent/ITRM20030596A1/it unknown
-
2004
- 2004-12-01 TW TW093137054A patent/TW200526246A/zh unknown
- 2004-12-21 AR ARP040104816A patent/AR047159A1/es not_active Application Discontinuation
- 2004-12-21 KR KR1020067012245A patent/KR20070000415A/ko not_active Application Discontinuation
- 2004-12-21 US US10/584,292 patent/US20070098722A1/en not_active Abandoned
- 2004-12-21 JP JP2006546487A patent/JP2007517021A/ja active Pending
- 2004-12-21 CA CA002548452A patent/CA2548452A1/en not_active Abandoned
- 2004-12-21 BR BRPI0418017-8A patent/BRPI0418017A/pt not_active IP Right Cessation
- 2004-12-21 EP EP04806879A patent/EP1706144A2/en not_active Ceased
- 2004-12-21 CN CNA2004800371947A patent/CN1893975A/zh active Pending
- 2004-12-21 MX MXPA06007080A patent/MXPA06007080A/es not_active Application Discontinuation
- 2004-12-21 WO PCT/IT2004/000714 patent/WO2005060997A2/en active Application Filing
- 2004-12-21 AU AU2004305341A patent/AU2004305341A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2007517021A (ja) | 2007-06-28 |
MXPA06007080A (es) | 2006-09-04 |
ITRM20030596A1 (it) | 2005-06-24 |
WO2005060997A2 (en) | 2005-07-07 |
KR20070000415A (ko) | 2007-01-02 |
EP1706144A2 (en) | 2006-10-04 |
TW200526246A (en) | 2005-08-16 |
AU2004305341A1 (en) | 2005-07-07 |
CN1893975A (zh) | 2007-01-10 |
CA2548452A1 (en) | 2005-07-07 |
BRPI0418017A (pt) | 2007-04-17 |
WO2005060997A3 (en) | 2005-09-09 |
US20070098722A1 (en) | 2007-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203960A1 (en) | Human protein tyrosine phosphatase inhibitors and their pharmaceutical use | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
AR025883A1 (es) | Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos | |
TW200642704A (en) | Oral drug delivery system and methods of use thereof | |
AR049876A1 (es) | Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos | |
CL2007002382A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel. | |
CL2004000836A1 (es) | Combinacion antineoplasica sinergica que comprende una combinacion de interferon alfa y cci-779; uso y producto que los contiene. | |
AR047159A1 (es) | Medicamento que comprende inhibidores de pentraxina larga ptx3 | |
BRPI0508865B8 (pt) | dispositivo de liberação de medicamento visível por raio x | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
EA200401227A1 (ru) | Система доставки лекарства с контролируемым высвобождением, включающая правастатин | |
ECSP045171A (es) | Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia | |
CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. | |
BRPI0516464B8 (pt) | método para a preparação de um produto farmacêutico | |
UY28335A1 (es) | Nueva combinación | |
CR9200A (es) | Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos | |
AR030140A1 (es) | Composiciones derivadas de la 2-piridinamina y metodos relacionados | |
AR046772A1 (es) | Medicamento que comprende ptx3, solo o en combinacion con tsg-6, para tratar enfermedades degenerativas de cartilago y hueso y tratar la infertilidad femenina | |
CY1116137T1 (el) | Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας | |
UA104714C2 (ru) | Выделенный полинуклеотид brachyspira hyodysenteriae, кодирующий полипептид, и его применение | |
BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
CL2004002030A1 (es) | Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata | |
HUP0401593A2 (hu) | A PTX3 hosszú pentraxin alkalmazása gyógyhatású készítmény előállítására autoimmun betegségek megelőzésére és kezelésére | |
BRPI0418764A (pt) | uso de espinosina ou um derivado ou sal da mesma fisiologicamente aceitável |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |